Memorial Sloan Kettering Cancer Center
SABCS 2021 Updates on Neratinib + Fulvestrant + Trastuzumab for HR+/HER2-Mutant MBC, and Neratinib + Trastuzumab for HER2-Mutant mTNBC: SUMMIT Trial Results
By
SABCS 2021 Conference Coverage on VuMedi
FEATURING
Komal Jhaveri
By
SABCS 2021 Conference Coverage on VuMedi
FEATURING
Komal Jhaveri
Login to view comments.
Click here to Login